Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared on X:
“Myeloma Paper of the Day:
A myeloid-dormant metabolic transcriptome identifies a poor-prognosis subgroup in hyperdiploid myeloma with targetable vulnerabilities, including ACSL1, which sensitizes to BCL-2 family inhibitors.”
Title: A myeloid-dormant metabolic transcriptome identifies a poor-prognosis subgroup in hyperdiploid multiple myeloma with targetable vulnerabilities
Authors: Naroa Barrena, Edurne San José-Enériz, Luis V. Valcárcel, Danel Olaverri-Mendizabal, Estibaliz Urizar-Compains, Leire Garate, Estíbaliz Miranda, Paula Rodriguez-Marquez, Romika Kumari, Patxi San Martín-Uriz, Juan Roberto Rodriguez-Madoz, Leonor Puchades-Carrasco, Caroline A. Heckman, Paula Rodriguez-Otero, Francisco J. Planes, Xabier Agirre, Felipe Prósper
You can read the full article on Blood Cancer Journal.
You can find other articles featuring Robert Orlowski on OncoDaily.
